- Home
- EVAX vs CYCN Comparison
EVAX vs CYCN Comparison
Compare EVAX & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- CYCN
- Stock Information
- Founded
- EVAX 2008
- CYCN 2018
- Country
- EVAX Denmark
- CYCN United States
- Employees
- EVAX N/A
- CYCN N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- CYCN Health Care
- Exchange
- EVAX Nasdaq
- CYCN Nasdaq
- Market Cap
- EVAX 8.7M
- CYCN 8.4M
- IPO Year
- EVAX 2021
- CYCN N/A
- Fundamental
- Price
- EVAX $2.49
- CYCN $3.12
- Analyst Decision
- EVAX Strong Buy
- CYCN
- Analyst Count
- EVAX 3
- CYCN 0
- Target Price
- EVAX $33.33
- CYCN N/A
- AVG Volume (30 Days)
- EVAX 6.9M
- CYCN 5.8M
- Earning Date
- EVAX 03-26-2025
- CYCN 03-04-2025
- Dividend Yield
- EVAX N/A
- CYCN N/A
- EPS Growth
- EVAX N/A
- CYCN N/A
- EPS
- EVAX N/A
- CYCN N/A
- Revenue
- EVAX $3,295,000.00
- CYCN $194,000.00
- Revenue This Year
- EVAX $9,039.73
- CYCN N/A
- Revenue Next Year
- EVAX $1.47
- CYCN N/A
- P/E Ratio
- EVAX N/A
- CYCN N/A
- Revenue Growth
- EVAX N/A
- CYCN N/A
- 52 Week Low
- EVAX $2.22
- CYCN $1.27
- 52 Week High
- EVAX $22.50
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- EVAX 39.85
- CYCN 46.78
- Support Level
- EVAX $2.30
- CYCN $2.81
- Resistance Level
- EVAX $2.80
- CYCN $4.80
- Average True Range (ATR)
- EVAX 0.51
- CYCN 0.76
- MACD
- EVAX 0.03
- CYCN -0.08
- Stochastic Oscillator
- EVAX 6.97
- CYCN 20.76
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.